Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02113397 · ClinicalTrials.gov registry record
Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- 1
- Enrollment target
NCT02113397 is a clinical trial that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT02113397 was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).
Interventions
- DRUG TOBI™ Podhaler™ 112 mg inhaled twice daily
- DRUG Colistimethate 75 mg inhaled two times daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02113397
The ClinicalTrials.gov registry entry for NCT02113397 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TOBI™ Podhaler™ 112 mg inhaled twice daily is the first listed.
NCT02113397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02113397 about?
NCT02113397 is a clinical study titled "Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung". The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).
What is the current status of trial NCT02113397?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2014-04. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02113397?
The interventions under investigation include: TOBI™ Podhaler™ 112 mg inhaled twice daily (DRUG), Colistimethate 75 mg inhaled two times daily (DRUG).
Who is sponsoring clinical trial NCT02113397?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.